Gilteritinib - Astellas Pharma

Drug Profile

Gilteritinib - Astellas Pharma

Alternative Names: ASP-2215; ASP2215 hemifumarate; Gilteritinib fumarate

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Amides; Aniline compounds; Antineoplastics; Piperazines; Piperidines; Pyrans; Pyrazines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 11 Dec 2017 Adverse events data from a phase I trial in Acute myeloid leukaemia presented at the Annual Meeting of the American Society of Haematology (ASH-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, First-line therapy) in Japan (PO, Tablet)
  • 20 Oct 2017 Astellas Pharma initiates an expanded access of gilteritinib for Acute myeloid leukaemia (In children, Second-line therapy or greater) in USA (NCT03315299)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top